SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study - potential challenge for vaccines and therapies.
South African and Brazil variants
UK variant B.1.1.7
high incidence of C to T transitions
numerous new mutations
time course of SARS-CoV-2 mutant emergence
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
07 06 2021
07 06 2021
Historique:
revised:
18
04
2021
received:
02
02
2021
accepted:
20
04
2021
pubmed:
2
5
2021
medline:
17
6
2021
entrez:
1
5
2021
Statut:
ppublish
Résumé
Scientists and the public were alarmed at the first large viral variant of SARS-CoV-2 reported in December 2020. We have followed the time course of emerging viral mutants and variants during the SARS-CoV-2 pandemic in ten countries on four continents. We examined > 383,500 complete SARS-CoV-2 nucleotide sequences in GISAID (Global Initiative of Sharing All Influenza Data) with sampling dates extending until April 05, 2021. These sequences originated from ten different countries: United Kingdom, South Africa, Brazil, United States, India, Russia, France, Spain, Germany, and China. Among the 77 to 100 novel mutations, some previously reported mutations waned and some of them increased in prevalence over time. VUI2012/01 (B.1.1.7) and 501Y.V2 (B.1.351), the so-called UK and South Africa variants, respectively, and two variants from Brazil, 484K.V2, now called P.1 and P.2, increased in prevalence. Despite lockdowns, worldwide active replication in genetically and socio-economically diverse populations facilitated selection of new mutations. The data on mutant and variant SARS-CoV-2 strains provided here comprise a global resource for easy access to the myriad mutations and variants detected to date globally. Rapidly evolving new variant and mutant strains might give rise to escape variants, capable of limiting the efficacy of vaccines, therapies, and diagnostic tests.
Identifiants
pubmed: 33931941
doi: 10.15252/emmm.202114062
pmc: PMC8185546
doi:
Substances chimiques
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Viral Nonstructural Proteins
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14062Subventions
Organisme : Dr. Robert Pfleger Stiftung in Bamberg, Germany
Informations de copyright
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Structure. 2021 Sep 2;29(9):951-962.e3
pubmed: 33930306
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
JAMA. 2021 Apr 6;325(13):1324-1326
pubmed: 33571356
Clin Infect Dis. 2021 Nov 16;73(10):1946-1947
pubmed: 33421056
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Virus Res. 2020 Nov;289:198170
pubmed: 32979477
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Curr Opin Lipidol. 2001 Apr;12(2):159-65
pubmed: 11264987
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
PLoS Biol. 2021 Mar 12;19(3):e3001115
pubmed: 33711012
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Cell Mol Immunol. 2020 Jun;17(6):621-630
pubmed: 32415260
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
EMBO Mol Med. 2021 Jun 7;13(6):e14062
pubmed: 33931941
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
mSphere. 2020 Jun 24;5(3):
pubmed: 32581081
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Emerg Infect Dis. 2021 May;27(5):1522-1524
pubmed: 33605869
N Engl J Med. 2021 Apr 8;384(14):e65
pubmed: 33826826
Nat Med. 2021 Apr;27(4):571-572
pubmed: 33649495
Cell. 2021 May 13;184(10):2587-2594.e7
pubmed: 33861950
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Sci Adv. 2020 Jun 17;6(25):eabb5813
pubmed: 32596474